COMMUNIQUÉS West-GlobeNewswire

Precipio Receives Expected Delisting Determination from Nasdaq Staff and Will Request Nasdaq Hearing
27/03/2019
NEW HAVEN, Conn., March 27, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ) today announced that it has received the expected delisting determination from Nasdaq Staff. The Company [...]
MediPharm Labs Sets Date to Release Fourth Quarter and Full Year 2018 Financial Results
27/03/2019
TORONTO, March 27, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MLCPF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, [...]
NEOVACS STRENGTHENS ITS FINANCIAL STRUCTURE: ISSUANCE OF "ORNANE" FOR A MAXIMUM AMOUNT OF €10M, WITHOUT STOCK SUBSCRIPTION WARRANTS
27/03/2019
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE N E OVACS STRENGTHENS ITS FINANCIAL STRUCTURE: ISSUANCE OF "ORNANE" FOR A MAXIMUM AMOUNT OF €10M, WITHOUT STOCK SUBSCRIPTION WARRANTS Paris and Boston, March 25 th 2019 - 7: [...]
BioCorRx Promotes Dr. Balbir S. Brar to Senior VP of Drug Development; Extends Service Agreement
27/03/2019
ANAHEIM, CA, March 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTC: BICX) (the "Company") , a developer and provider of advanced solutions in the treatment of substance abuse disorders, today [...]
Bellicum Pharmaceuticals to Participate in Jefferies 6th Annual IO Cell Therapy Summit
27/03/2019
HOUSTON, March 27, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) , a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]
Affimed Reports 2018 Financial Results and Operational Progress
27/03/2019
- AFM13: Encouraging data supports initiation of monotherapy registration-directed study in first half of 2019; Combination study with cord blood-derived natural killer cells planned to initiate at MD Anderson; Clinical [...]
Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007
27/03/2019
- Phase 3 clinical trial, named DEFI-RDEB, is expected to commence in the second quarter of 2019 - - Additional data from Phase 1/2 clinical trial demonstrates FCX-007 continues to be well tolerated with continued [...]
Centrexion Therapeutics Announces Publication of Phase 2 Efficacy Data on CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain in Arthritis & Rheumatology
27/03/2019
BOSTON, March 27, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation (Centrexion) , a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today announced [...]
Assembly Biosciences Announces Multiple Abstracts Highlighting HBV Core Inhibitor Portfolio Accepted for Oral and Poster Presentations at EASL 2019
27/03/2019
SAN FRANCISCO, March 27, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases [...]
Dermavant Sciences Announces Appointment of Cyril Allouche as Chief Financial Officer and Provides Recent Corporate Update
27/03/2019
Mr. Allouche has over 20 years of combined experience in finance leadership, audit, and advisory roles, most recently serving as Principal Accounting Officer, Head of Finance, and Corporate Controller at Revance [...]
Supreme Cannabis Scales Up Production & Into Higher Margin Product Lines -- CFN Media
27/03/2019
SEATTLE, March 27, 2019 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article featuring [...]
Final Results
27/03/2019
Summit Therapeutics plc (‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2019 and Operational Progress Focus on Improving [...]
CB2 Insights Signs Agreement with Premier Health to Integrate Medical Cannabis Clinical Decision Support Tool
27/03/2019
First-of-its-Kind EMR Platform Integration to Provide Tool for Nearly 5,000 Physicians and Healthcare Practitioners to Qualify and Prescribe Medical Cannabis TORONTO, March 27, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (CSE [...]
Aclaris Therapeutics to Attend Upcoming Investor Conference
27/03/2019
WAYNE, Pa., March 27, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today announced that [...]
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder
27/03/2019
Designation offers potential for expedited development and review NEW YORK, March 27, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel [...]
CFN Media Interviews High Hampton’s CEO to Discuss 2019 Catalysts
27/03/2019
SEATTLE, March 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an [...]
Eyenovia Reports Fourth Quarter and Full Year 2018 Financial Results
27/03/2019
NEW YORK, March 27, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print [...]
Tetra Bio-Pharma to File PPP001 With the European Medicines Agency
27/03/2019
OTTAWA, March 27, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX-V: TBP) (OTCQB: TBPMF) , today announced it is ready to submit its PPP001 cannabinoid-derived drug as a herbal [...]
Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial
27/03/2019
- Completed enrollment in ACH-4471 Phase 2 PNH trial in combination with eculizumab - - Interim data to be released in May 2019 - - Targeting FDA end-of-Phase 2 meeting in second half of 2019 - BLUE BELL, Pa., March 27 [...]

Pages